Peer-reviewed veterinary case report
Maintenance treatment after CHOP-LAsp chemo extends remission in dogs
By Lautscham, E M et al.·Published in The Veterinary record·2017·Small Animal Clinic Hofheim, Germany·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Comparison of a CHOP-LAsp-based protocol with and without maintenance for canine multicentric lymphoma.
- Species:
- dog
Plain-English summary
A study looked at how well two different treatment plans worked for dogs with multicentric lymphoma, a type of cancer. One group of 75 dogs received a full treatment plan that included a maintenance phase for two years, while another group of 333 dogs stopped treatment after the initial phase. The results showed that both groups had similar survival times, with the maintenance group living a median of about 375 days and the other group about 304 days. Overall, the study suggests that stopping treatment after the initial phase is still effective for managing this type of cancer in dogs.
People also search for: dog lymphoma treatment options · canine cancer survival rates · lymphoma in dogs prognosis
Abstract
The recommendation to treat canine lymphoma with a discontinuous protocol is based on small case numbers and mostly historic controls. This study compares duration of first remission (DFR) and overall survival time (ST) with a discontinuous protocol to the same protocol with maintenance phase. 408 dogs were treated with a CHOP-LAsp (C=cyclophosphamide; H=hydroxydaunorubicin; O=Oncovin; P=prednisolone; LAsp=l-asparaginase)-based 28-week induction protocol. In 75 dogs (cohort 1), this was followed by a maintenance phase consisting of vincristine, chlorambucil and actinomycin-D with a total treatment duration of two years. In the subsequent 333 dogs, therapy was discontinued after induction (cohort 2). Median DFR and ST in cohort 1 were 216 and 375 days and 184 and 304 days in cohort 2. 6-Month, 1-year and 2-year survival rates in cohort 1 were 73 per cent, 50 per cent, 24 per cent and 67 per cent, 39 per cent, 21 per cent in cohort 2. There was no significant difference between the two protocols (P=0.291 for ST, P=0.071 for DFR). On multivariate analysis, corticosteroid pretreatment (P=0.005), thrombocytopenia at diagnosis (P=0.019), stage (P=0.009), substage b at relapse (P<0.001), age (P=0.002) and incomplete or unstable remission necessitating intensification of therapy (P=0.004) were negatively correlated with ST in both groups. This study supports the use of a discontinuous protocol for canine multicentric lymphoma.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/28100766/